Edwards Lifesciences

Edwards Lifesciences rebounded sharply in post-market trading today, buoyed by better-than-expected Q2 results. The company reported Q2 revenue of $1.741 billion, up 13.6% year-over-year, and adjusted EPS of $0.78, beating the consensus estimate of $0.74; management raised full-year guidance, citing strong growth in TAVR (transcatheter aortic valve replacement) and TMTT (transcatheter mitral and tricuspid valve therapies). Intraday trading showed divergence, with the stock declining 0.65% to close at $83.82, but staged a strong recovery to $89.95 in after-hours trading, representing a 7%+ gain from the closing price. From a valuation standpoint, the stock is down 1.77% year-to-date and trades 12.95% below its 52-week high of $96.29. The elevated PE ratio of 44.03x may constrain further upside.

Edwards Lifesciences exhibited sharp intra-day divergence, surging to $85.90 in pre-market before profit-taking mounted through the regular and after-hours sessions. The stock closed at $84.37, down 0.21% from the prior day, and slipped further to $83.00 in extended trading. It has retreated 12.38% from its July 7 52-week high of $96.29 and now trades below both the 20-day moving average ($90.10) and 60-day moving average ($86.33). Fundamentals remain robust: Q1 revenue of $1.65 billion grew 16.7% year-over-year, with operating profit accelerating at 25.57% and net margin solid at 23.1%. Investors await tomorrow's (July 23) earnings call. Citigroup and BTIG Research both maintain a $110 price target. Large shareholder Edwards Lifesciences Holding recently raised its stake to 11.65%, signaling confidence, though recent insider selling suggests near-term profit-taking headwinds. The PE valuation of 44.3x reflects market caution.

EW slipped slightly today as investors digest the recent pullback from its 52-week high of 96.29 reached just two weeks ago, with the stock now trading at 84.55, down 12.19%. Ahead of the Q2 2026 earnings call scheduled for July 23, market sentiment has been tempered by the prior quarter's disappointing results—Q4 2025 saw EPS plummet 76.59% year-over-year—though Q1 2026 showed signs of stabilization with revenue of 1.65 billion USD, up 16.7% YoY and EPS recovering with 8.15% growth. The stock currently trades roughly 2% below its 60-day moving average of 86.33, and is down just 0.91% year-to-date. However, both Citigroup and BTIG Research maintain a 110 USD price target, suggesting analyst confidence in the company's medium-term trajectory, though the elevated valuation multiple of 44.4x PE reflects high market expectations for sustained growth.

EW declined 0.85% to close at $85.00 today, primarily reflecting profit-taking ahead of the earnings call scheduled for July 23, 2026. Q1 results were robust, with revenue of $1.65B up 16.7% year-over-year and net margin expanding to 23.09%; EPS reached $0.66, up 8.15% YoY. Recent clinical progress also supports the thesis — the LuX-Valve Plus tricuspid valve system completed its first implants in the FDA pivotal trial, marking a significant milestone. Both Citigroup and BTIG Research set price targets at $110, implying roughly 29% upside from current levels. However, the elevated valuation at a PE of 44.65 reflects heightened growth expectations, and the stock remains 11.72% below its 52-week high of $96.29, down just 0.39% year-to-date.

EW.US declined 2.4% today as premarket optimism faded, rallying to 89.187 early but retreating to 85.730 by close, reflecting profit-taking and caution ahead of Q2 earnings on July 23. Recent Q1 2026 results showed strong momentum: revenue of $1.649B grew 16.7% year-over-year with net margins expanding to 23.09%, and EPS rose 8.15% YoY, a stark recovery from Q4 2025's weakness with margins at 5.81% and EPS declining 76.59%. The stock trades roughly 11% below the 52-week high of $96.29 set in early July, yet the elevated valuation of 45x PE reflects market expectations for continued growth. Both Citigroup and BTIG maintain $110 price targets, implying approximately 28% upside, though investors remain cautious approaching the earnings announcement.